A global, randomized, open-label Phase 2 clinical trial in patients with high-risk, resectable melanoma to evaluate the neoadjuvant treatment combination of the Tavokinogene telseplasmid administered intratumorally by electroporation (TAVO-EP) with intravenous KEYTRUDA (pembrolizumab)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 30 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Tavokinogene telseplasmid (Primary)
Indications Malignant melanoma
Focus Therapeutic Use

Most Recent Events

30 May 2023 New trial record
16 May 2023 According to a OncoSec Medical media release, the company had held a Type C meeting held with the US Food and Drug Administration (FDA) to discuss the trial design of this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight